These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 18612128)

  • 21. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
    Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
    Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improving breast cancer risk prediction by using demographic risk factors, abnormality features on mammograms and genetic variants.
    Feld SI; Woo KM; Alexandridis R; Wu Y; Liu J; Peissig P; Onitilo AA; Cox J; Page CD; Burnside ES
    AMIA Annu Symp Proc; 2018; 2018():1253-1262. PubMed ID: 30815167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved breast cancer prognosis through the combination of clinical and genetic markers.
    Sun Y; Goodison S; Li J; Liu L; Farmerie W
    Bioinformatics; 2007 Jan; 23(1):30-7. PubMed ID: 17130137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing thyroid cancer risk using polygenic risk scores.
    Liyanarachchi S; Gudmundsson J; Ferkingstad E; He H; Jonasson JG; Tragante V; Asselbergs FW; Xu L; Kiemeney LA; Netea-Maier RT; Mayordomo JI; Plantinga TS; Hjartarson H; Hrafnkelsson J; Sturgis EM; Brock P; Nabhan F; Thorleifsson G; Ringel MD; Stefansson K; de la Chapelle A
    Proc Natl Acad Sci U S A; 2020 Mar; 117(11):5997-6002. PubMed ID: 32132206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Variation in predictive ability of common genetic variants by established strata: the example of breast cancer and age.
    Aschard H; Zaitlen N; Lindström S; Kraft P
    Epidemiology; 2015 Jan; 26(1):51-8. PubMed ID: 25380502
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Utility of incorporating genetic variants for the early detection of prostate cancer.
    Nam RK; Zhang WW; Trachtenberg J; Seth A; Klotz LH; Stanimirovic A; Punnen S; Venkateswaran V; Toi A; Loblaw DA; Sugar L; Siminovitch KA; Narod SA
    Clin Cancer Res; 2009 Mar; 15(5):1787-93. PubMed ID: 19223501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive model for risk of gastric cancer using genetic variants from genome-wide association studies and high-evidence meta-analysis.
    Qiu L; Qu X; He J; Cheng L; Zhang R; Sun M; Yang Y; Wang J; Wang M; Zhu X; Guo W
    Cancer Med; 2020 Oct; 9(19):7310-7316. PubMed ID: 32777176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of single nucleotide polymorphisms in FGF-RAS/MAP signalling cascade with breast cancer susceptibility.
    Dankova Z; Zubor P; Grendar M; Kapinova A; Zelinova K; Jagelkova M; Gondova A; Dokus K; Kalman M; Lasabova Z; Danko J
    Gen Physiol Biophys; 2017 Dec; 36(5):565-572. PubMed ID: 29372690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abnormal miRNA-30e Expression is Associated with Breast Cancer Progression.
    Lin Z; Li JW; Wang Y; Chen T; Ren N; Yang L; Xu W; He H; Jiang Y; Chen X; Liu T; Liu G
    Clin Lab; 2016; 62(1-2):121-8. PubMed ID: 27012041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population analysis of microsatellite genotypes reveals a signature associated with ovarian cancer.
    Fonville NC; Vaksman Z; McIver LJ; Garner HR
    Oncotarget; 2015 May; 6(13):11407-20. PubMed ID: 25779658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer.
    Le Rhun E; Bertrand N; Dumont A; Tresch E; Le Deley MC; Mailliez A; Preusser M; Weller M; Revillion F; Bonneterre J
    Eur J Cancer; 2017 Dec; 87():189-198. PubMed ID: 29103666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a genetic marker set to diagnose aspirin-exacerbated respiratory disease in a genome-wide association study.
    Chang HS; Shin SW; Lee TH; Bae DJ; Park JS; Kim YH; Uh ST; Choi BW; Kim MK; Choi IS; Park BL; Shin HD; Park CS
    Pharmacogenomics J; 2015 Aug; 15(4):316-21. PubMed ID: 25707394
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel 18-Marker Panel Predicting Clinical Outcome in Breast Cancer.
    Biermann J; Nemes S; Parris TZ; Engqvist H; Rönnerman EW; Forssell-Aronsson E; Steineck G; Karlsson P; Helou K
    Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1619-1628. PubMed ID: 28877888
    [No Abstract]   [Full Text] [Related]  

  • 34. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
    Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
    J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating Prognostic Markers Using Relative Utility Curves and Test Tradeoffs.
    Baker SG; Kramer BS
    J Clin Oncol; 2015 Aug; 33(23):2578-80. PubMed ID: 26124476
    [No Abstract]   [Full Text] [Related]  

  • 36. Limits of predictive models using microarray data for breast cancer clinical treatment outcome.
    Reid JF; Lusa L; De Cecco L; Coradini D; Veneroni S; Daidone MG; Gariboldi M; Pierotti MA
    J Natl Cancer Inst; 2005 Jun; 97(12):927-30. PubMed ID: 15956654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes.
    Curtit E; Pivot X; Henriques J; Paget-Bailly S; Fumoleau P; Rios M; Bonnefoi H; Bachelot T; Soulié P; Jouannaud C; Bourgeois H; Petit T; Tennevet I; Assouline D; Mathieu MC; Jacquin JP; Lavau-Denes S; Darut-Jouve A; Ferrero JM; Tarpin C; Lévy C; Delecroix V; Trillet-Lenoir V; Cojocarasu O; Meunier J; Pierga JY; Kerbrat P; Faure-Mercier C; Blanché H; Sahbatou M; Boland A; Bacq D; Besse C; Thomas G; Deleuze JF; Pauporté I; Romieu G; Cox DG
    Breast Cancer Res; 2017 Aug; 19(1):98. PubMed ID: 28830573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
    Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
    J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing the performance of genome-wide association studies for predicting disease risk.
    Patron J; Serra-Cayuela A; Han B; Li C; Wishart DS
    PLoS One; 2019; 14(12):e0220215. PubMed ID: 31805043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.